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Abstract Study	Design
Western	blot	analysis	was	
used	to	probe	for	FAAH	
expression	in	the	human	
breast	cancer	cell	lines.	
Then,	individual	apoptotic	
effects	of	FAAH	inhibitors	
(URB597	and	PF750)	and	
endocannabinoids	(AEA	
and	PEA)	were	tested	
using	MTT	assays.
Probe	for	FAAH	Expression
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Background:	Breast	cancer	is	a	highly	heterogeneous,	aggressive	disease	that	
has	poor	prognosis.	Current	treatment	is	present,	but	research	on	a	therapeutic	
alternative	is	ongoing.	Endocannabinoids,	members	of	the	endocannabinoid	
system,	are	naturally	produced	by	cells	in	our	bodies.	They	are	diverse	signaling	
components	that	have	several	functions,	including	regulation	of	the	apoptosis	
mechanism.	Fatty	Acid	Amide	Hydrolase	(FAAH)	is	an	integral	membrane	
enzyme	that	hydrolyzes	endocannabinoids,	rendering	them	inactive.	Since	
FAAH	is	upregulated	in	cancer	cells,	FAAH	inhibition	is	predicted	to	increase	the	
apoptotic	rate.	
Methods:	To	test	the	effects	of	FAAH	inhibitors	and	exogenous	
endocannabinoids,	cells	were	cultured,	probed	for	FAAH	expression	using	
Western	blot	analysis,	treated	with	FAAH	inhibitors,	exogenous	
endocannabinoids,	and	combinations	of	both,	all	in	varying	doses,	and	cell	
viability	was	measured	using	MTT	assays.	
Results:	High	levels	of	FAAH	were	observed	in	two	breast	cancer	cell	lines.	The	
greatest	change	was	observed	at	50	µm	PF-750	treatment,	which	is	the	most	
selective	FAAH	inhibitor.	URB597	combination	treatments	decreased	cell	
viability	in	a	supra-additive	manner.		The	most	significant	change	was	observed	
at	co-treatment	levels	of	50	µm	URB597	and	50	µm	AEA,	which	resulted	in	a	
30%	decrease	(p<0.001)	in	cell	viability	compared	to	vehicle	control.	FAAH	
inhibition	was	more	effective	than	exogenous	endocannabinoid	use,	and	
combination	treatments	of	FAAH	inhibitors	and	exogenous	endocannabinoids,	
both	at	the	highest	doses,	were	the	most	effective.
FAAH	inhibition	is	a	promising	
approach	to	induce	cell	death	
in	breast	cancer	cells.	Studies	
are	in	progress	to	test	the	in-
vivo	efficacy	of	FAAH	inhibition	
and	the	underlying	pathogenic	
mechanisms.	
(A) Western	Blot	demonstrating	expression	of	FAAH,	using	α-Tubulin	as	house-keeping	control.	(B)	FAAH	shown	normalized	against	α-Tubulin.	(C)	Cell	viability	(%)	of	breast	cancer	cell	lines	MCF7,	MDA-MB-231,	and
T47D,	caused	by	endocannabinoid,	AEA.	(D)	Cell	viability	(%)	of	breast	cancer	cell	lines	MCF7,	MDA-MB-231,	and	T47D,	caused	by	endocannabinoid,	PEA.	(E)	Cell	viability	(%)	of	breast	cancer	cell	lines	MCF7,	MDA-MB-
231,	and	T47D,	caused	by	FAAH	inhibitor,	URB597.	Data	are	expressed	as	percent	cell	viability	normalized	to	the	vehicle	control	with	n≥3.	Statistical	significance	are	relative	to	vehicle	control	and	are	assigned	as
follows:	*,	 P	<	0.05;	**,	P	<	0.01;	***,	P	<	0.001.
Conclusion:	FAAH	inhibitor,	URB597,	produces	varying	effects	in	different	cell	lines,	but	is	more	effective	than	exogenous	endocannabinoids,	AEA	and	PEA,	and	has	more	of	a	dose-dependent	response	for	cell	viability.
(F) Cell	viability	(%)	of	breast	cancer	cell	lines	MCF7,	MDA-MB-231,	and	T47D,	caused	by	FAAH	inhibitor,	PF-750.	(G)	Cell	viability	(%)	of	breast	cancer	cell	lines
MCF7,	MDA-MB-231,	and	T47D,	caused	by	combination	treatment	of	FAAH	inhibitor,	URB597,	and	endocannabinoid,	AEA.	(H)	Cell	viability	(%)	of	breast	cancer	cell
lines	MCF7,	MDA-MB-231,	and	T47D,	caused	by	combination	treatment	of	FAAH	inhibitor,	URB597,	and	endocannabinoid,	PEA.	Data	are	expressed	as	percent	cell
viability	normalized	to	the	vehicle	control	with	n≥3.	Statistical	significance	are	relative	to	vehicle	control	and	are	assigned	as	follows:	*,	P	<	0.05;	**,	P	<0.01;	***,
P	<	0.001.
Conclusion:	FAAH	inhibitor,	PF-750,	produced	the	most	promising	results	in	cell	line,	MDA-MB-231,	as	did	URB597	for	this	cell	line.	FAAH	inhibitor	and	exogenous
endocannabinoid	combination	treatment	is	the	most	effective	means	of	decreasing	cancer	cell	viability,	especially	at	the	highest doses	of	each.
Binding	of	extracellular	anandamide (triangles)	
to	type	1	or	2	cannabinoid	receptors(CB1R	or	
CB2R)	triggers	different	signal	transduction	
pathways,	depending	on	the	cell	type.	
Activation	of	either	CB1R	or	CB2R	increases	
intracellular	levels	of	ceramide,	which	activates	
Raf1/ERK	cascade,	thus	engaging	JNK/p38	
MAPK	along	the	pathway	leading	to	apoptosis.
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